 CHARLOTTESVILLE, VA ACCESSWIRE April 16, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced that the functionality of its proprietary companion diagnostic genetic test has been verified as clinically effective through its utilization in the landmark ONWARDTM pivotal Phase 3 clinical trial of the Companys lead drug candidate, ultra-low dose ondansetron AD04, for the treatment of Alcohol Use Disorder AUD. The Company expects to expand the use of the genetic test into clinical trials of AD04 in the future for the treatment of other indications such as Opioid Use Disorder OUD and is working to establish testing capacity in the United States for future studies. 